India Tightens Watch on GLP-1 Drugs Amid Safety and Misuse Concerns
India's drug regulators are intensifying GLP-1 oversight ahead of semaglutide's patent expiry. The Drug Controller General audited 49 entities and issued notices to violators.
#india
7 stories
India's CDSCO Tightens Oversight on GLP-1 Drugs, Warns Against Weight Loss Misuse
India's Central Drugs Standard Control Organization issued advisories against unsupervised use of semaglutide and tirzepatide for weight loss, cracking down on misleading social media promotions and unapproved compounded versions.
Novo Nordisk Slashes Ozempic and Wegovy Prices Up to 48% in India
Novo Nordisk cut Ozempic prices 36% and Wegovy 48% in India as generic semaglutide from Dr Reddy's, Sun Pharma, and Zydus entered the market with prices as low as Rs 1,290/month.
Novo Nordisk Price Cuts Expected to Reshape India GLP-1 Market
Analysts expect Novo's aggressive cuts to capture the lion's share of India's GLP-1 market in 12-18 months. Eli Lilly's Mounjaro currently dominates with ~79% share vs Novo's ~21%.
India Semaglutide Prices Expected to Drop 70% as 50+ Generics Enter Market
Following Novo Nordisk's patent expiry on March 20, more than 50 generic semaglutide versions are anticipated in India, dramatically expanding GLP-1 access.
India Semaglutide Trademark Disputes: Dr. Reddy's Renames Drug After Court Concerns
Dr. Reddy's will rename its semaglutide drug from 'Olymviq' to 'Olymra' after Delhi High Court flagged similarity to Novo Nordisk's 'Ozempic'. Fierce competition in India's generic market.
Biocon Skips India's Crowded Generic Semaglutide Market, Eyes Global Expansion
Biocon's incoming CEO said the company will prioritize Canada, Brazil, and the Middle East instead of India's saturated GLP-1 market with 40+ generic entrants.